32results about How to "Sufficient efficacy" patented technology

The invention features modular chambers for culturing cells in which the volume of a chamber can be adjusted without compromising the seal or sterility of the chamber. The invention is based on the principle that the volume of a chamber formed between two plates sandwiching a compressible gasket and a substantially incompressible stop can be adjusted using a gasket that forms a fluid-tight seal between the plates at a plurality of levels of compression. The invention enables the culture of cells between substantially parallel and rigid plates in which a relatively large volume can be used to seed the cells and the holdup volume reduced for perfusion without opening or otherwise disassembling the system to compromise its liquidtightness and sterility. The new closed, modular and scalable cell-culturing chamber can be thus perfused and used to culture cells (e.g., hepatocytes) with high levels of cell function in organ (e.g., liver) assist systems, for production of cells, for production of cell-derived products, such as proteins or viruses, or for systems to treat biological liquids to remove toxins, such as ammonia, add cell-synthesized products, or both.

A fan type chemical diffusing apparatus includes an apparatus main body having an air inlet and an air outlet, a fan type blower disposed in the apparatus main body, and an active ingredient impregnated body or mass for containing an active ingredient. The fan type blower includes a fan casing, a motor, and a fan including a rotary disk and a plurality of blades fastened to a peripheral portion of the rotary disk and provided with a hollow space that is on an interior of the fan with respect to the blades. The fan type blower is operable to send air from the air inlet through the hollow space and out through the air outlet.

The invention features modular chambers for culturing cells in which the volume of a chamber can be adjusted without compromising the seal or sterility of the chamber. The invention is based on the principle that the volume of a chamber formed between two plates sandwiching a compressible gasket and a substantially incompressible stop can be adjusted using a gasket that forms a fluid-tight seal between the plates at a plurality of levels of compression. The invention enables the culture of cells between substantially parallel and rigid plates in which a relatively large volume can be used to seed the cells and the holdup volume reduced for perfusion without opening or otherwise disassembling the system to compromise its liquidtightness and sterility. The new closed, modular and scalable cell-culturing chamber can be thus perfused and used to culture cells (e.g., hepatocytes) with high levels of cell function in organ (e.g., liver) assist systems, for production of cells, for production of cell-derived products, such as proteins or viruses, or for systems to treat biological liquids to remove toxins, such as ammonia, add cell-synthesized products, or both.

A fan type debugging apparatus is provided in which the active ingredient impregnated body or mass is disposed in a wind inlet side of the fan type blower and is designed to provide a wind force resistance which in terms of the proportion of current consumption by the motor in the presence of the active ingredient impregnated body or mass to current consumption by the motor in the absence of the active ingredient impregnated body or mass, ranges from 5 to 25%.

The present invention relates to guanidine compounds of the general formula Icorresponding enantiomeric, diastereomeric and / or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.

[Problem]To provide a therapeutic agent for irritable bowel syndrome (IBS), which is excellent in efficacy and safety.[Means for Resolution]It was shown that the bombesin 2 (BB2) receptor antagonists typified by RC-3095 are therapeutic agents for irritable bowel syndrome (IBS), which show excellent efficacy in both of an abdominal symptom and bowel movement disorder. Thus, according to the present invention, it became possible to provide a therapeutic agent for irritable bowel syndrome (IBS) which comprises, as an active ingredient, a bombesin 2 (BB2) receptor antagonist exerting an excellent efficacy in both an abdominal symptom and bowel movement disorder.

An optical radiation coupling module includes a waveguide for the propagation of optical radiation, an optoelectronic device arranged on a substrate, and a mechanism for coupling the radiation between the waveguide and the optoelectronic device. The coupling mechanism includes a guiding element moulded and tapered in a radiation propagation direction.

A compound represented by the following formula (1):wherein R1 is an aldopyranose residue wherein the 6-hydroxyl group is optionally alkylated, R2 is a C1-26 hydrocarbon group optionally having substituent(s), R3 is a hydrogen atom or a C1-26 hydrocarbon group optionally having substituent(s), R4 is a C1-21 hydrocarbon group optionally having substituent(s), X is an oxygen atom or —CH2—, and Y is —CH2—, —CH(OH)— or —CH═CH—, or a salt thereof is useful for the prophylaxis or treatment of cancer or infection, since it can preferentially induce production of IFN-γ of NKT cells.

The present invention is related to a UV CCFL lamp, and more particularly, to a UV CCFL lamp for curing a nail gel with a UVA irradiation having a peak wavelength of such as 366 nm or 368 nm in the field of nail art. In order to provide a UV CCFL lamp capable generating ultraviolet light of high intensity and uniform lighting with great electrical safety and reliability, the UV CCFL lamp of the present invention comprises a translucent hermetic envelope configured to enclose a discharge medium and a UV-excited phosphor to generate the desired UV irradiation preferably in the UVA spectrum range. The discharge medium is preferably to be a mercury-ion vapor and distributed throughout and sealed within the lamp envelope to be excited to a plasma state and for producing a first emission spectrum of a UVC wavelength during operation; and the phosphor in contact with the mercury-ion vapor plasma preferably comprises a composition of either europium-doped boron strontium oxide (B4SrO7:Eu+) or europium-doped strontium fluoborate (SrFB2O3.5:Eu2+) for producing said UV irradiation in response to said first emission spectrum of the discharge medium. To provide a uniform UV irradiation output from the UV CCFL lamp of the present invention, the phosphor is advantageously prepared to be of a mean grain size of 8.5μm±3μm for SrFB2O3.5:Eu2+ and of 15μm±3μm for B4SrO7:Eu+.

The present invention relates to implantable endoluminal prosthesis for preventing stroke. The endoluminal prosthesis (1) consists of a braided framework (20) defining a cylindrical lumen (21) devoid of impermeable membrane. Said braided framework (20) is self-expandable comprising a plurality of layers (22, 23, 24) of wires (25) made of biocompatible material. Each layer forms a mesh. The meshes form a lattice with a plurality of wires (2) of given layers (22, 23, 24). The lattice defines polygonal opening units (26) when observed normal to a wall of the implantable endoluminal prosthesis (1). The diameter (Ø25) of wire (25) being at least 30 μm and at most 150 μm, the mean diameter (Ø27) of the inscribed circle (27) of the polygonal opening units (26) being at least 75 μm and at most 200 μm in fully expanded state. The braided framework (20) consists of at least 128 and at most 512 wires (25). The ratio (T1 / Ø25) of the thickness (T1) of a wall of said implantable endoluminal prosthesis (1) to the diameter (Ø25) of wire (25) is at least 3.0. In a fully expanded state, the surface coverage ratio (SCR) of said braided framework (20) is more than 50% and less than 90%.

The present invention provides compositions and methods for treatment of metabolic syndromes. Namely, the presently disclosed compositions and methods are provided for affecting the function of the gastrointestinal endocrine system in key regions of the gut, thereby, producing therapeutic effects on obesity, diabetes and other metabolic disorders. The compositions include components for forming luminal barriers within the gastrointestinal tract of a subject where the barrier is created in-situ via interaction of resident mucin with the mucin-interacting agent.

A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.

The present invention provides an oral composition comprising: (a) from 1 wt % to 60 wt % of a calcium-containing abrasive; (b) a calcium-catching phosphate source in an amount sufficient to provide at least 100 mM of phosphate ions, PO43−; (c) no more than 20 wt % of a humectant; and (d) at least 5 wt % of water; wherein the oral composition has a pH from 8 to 11.

Illumination devices with improved color mixing optics are disclosed herein for mixing the colors produced by a multi-colored LED emitter module to produce uniform color throughout the entire beam angle of the output light beam, along with smoother edges and improved center beam intensity. Embodiments disclosed herein include a unique arrangement of multi-color LEDs within an emitter module, a unique exit lens with different patterns of lenslets on opposing sides of the lens, and other associated optical features that thoroughly mix the different color components, and as such, provide uniform color across the output beam exiting the illumination device. Additional embodiments disclosed herein include a unique arrangement of photodetectors within the primary optics structure of the LED emitter module that ensure the optical feedback system properly measures the light produced by all similarly colored emission LEDs.

The present invention relates to guanidine compounds of the general formula Icorresponding enantiomeric, diastereomeric and / or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.

A 5α-androstane-3β,5,6β-triol injection and its preparation are disclosed. The injection uses hydroxypropyl-β-cyclodextrin as a solubilizing agent and the active ingredient is present at a weight ratio of 1-20:40-500 to the hydroxypropyl-β-cyclodextrin. The injection may also comprise, by weight, 1-100 parts of at least one isotonic adjusting agent, 0-200 parts of at least one freeze drying filler, and 0-2000 parts of at least one solvent. The preparation method comprises dissolving hydroxypropyl-β-cyclodextrin solution, 5α-androstane-3β,5,6β-triol and at least one additional soluble excipient in water for injection in sequence to obtain a raw injection solution, and subjecting the raw injection solution to decolorization, depyrogenation, filtration and sterilization to obtain the injection, Drying the filtrate yields a solid for injection.

Disclosed is an antimicrobial composition containing an active halogen-containing component having a source of an active halogen and having an elevated pH, which is mixed with an acidic component. An acidic component is added in an amount to the active halogen-containing component to reduce the pH of the antimicrobial composition. When the pH of the active halogen-containing composition is reduced, the resulting composition has been discovered to be effective as a disinfectant and, particularly, as a sporicide. Application methods for applying the composition are also described.